A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 233 participants.

Also called NCT05563246

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 233 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05563246
  • EU CT 2022-501466-21-00
Other papers using this trial's data
  • Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial JAMA, 2025-01-21 DOI, PubMed 39556768, PMC11574718 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, China, Germany, Hungary, Japan, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05563246. Randomized; double masking; primary purpose treatment. Start 2022-11-24 (actual); primary completion 2024-03-14 (actual). Results posted on 2025-03-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Acronym
KRAKEN
Condition
Lipoprotein Disorder
Intervention (Drug)
LY3473329
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05563246
Content hash
7b7859a19f1fa03d0d5cac59ef401675053a218287a26b6d811297367117d62f